THERMALIN DIABETES, LLC

CLEVELAND, OH · Founded 2010 · Biotech · Private

Ultra-stable, ultra-fast insulin analog formulation resistant to fibrillation at body and room temperature

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026

Sector: Biotech
Headquarters: CLEVELAND, OH
Founded: 2010
Latest Form D: $2.5M, Sep 2013
Total capital: $8M

Federal grants: $439K; 3 awards · 2015–2016; Rank in peer group#326 of 502
Private capital raised: $7.6M; 3 Form D · last Sep 2013; 158 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 1; 1 pending · first 2018; Rank in peer group#57 of 502

Capital timeline

Latest events

Sep 2016Federal grantHealth and Human S · Phase I · Enabling implantable artificial pancreas pumps with heat-stable, ultra-rapid insulin$77K
Sep 2015Federal grantHealth and Human S · Phase I · Optimizing diabetes therapy: re-engineering insulin as a biased agonist$141K
Apr 2015Federal grantHealth and Human S · Phase II · Fluorolog: A Rapid-Acting Ultra-Concentrated Insulin Formulation$221K
Sep 2013Private capital raisedForm D · SEC · 3rd filing$2.5M
Jul 2013Private capital raisedForm D · SEC · 2nd filing$3.1M
Oct 2010Private capital raisedForm D · SEC · 1st filing$1.9M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 502 peers

Line = median

Biotech · Molecule

Federal grantsBelow median
Granted patents#57 · top 11%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings

Bruce H. FrankExecutive OfficerNamed in SEC Form D filings
Gerald WislerDirectorNamed in SEC Form D filings
Jeffrey EltonDirectorNamed in SEC Form D filings
John BrooksDirectorNamed in SEC Form D filings
Joseph JankowskiDirectorNamed in SEC Form D filings
Michael WeissDirectorNamed in SEC Form D filings

Show all 10 people

Mitchell BriskinExecutive OfficerNamed in SEC Form D filings
Raymond RackleyDirectorNamed in SEC Form D filings
Richard BerensonExecutive Officer, DirectorNamed in SEC Form D filings
Steven TregayDirectorNamed in SEC Form D filings

What it has protected

USPTO · 1 granted of 2

Feb 27, 2018GrantedRapid Action Insulin Formulations And Pharmaceutical Delivery SystemsUSPTOUS 9,901,622
PendingRapid Action Insulin Formulations And Pharmaceutical Delivery SystemsUSPTOApplication PCTUS2015011202

GROW BIOMEDICINE LLCSimilar federal contract value in Biotech · null in contracts
LUNG THERAPEUTICS INCSimilar federal contract value in Biotech · null in contracts
CLARADELE PHARMACEUTICALS, INCORPORATEDSimilar federal contract value in Biotech · null in contracts
CYTODEL, INC.Similar federal contract value in Biotech · null in contracts
ASYLIA THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
Maia Biotechnology, Inc.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.